Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Tries Genentech Formula In Japan: Chugai Deal Follows 1990 Model

Executive Summary

Roche will have "opt-in" rights on Chugai's Phase II rheumatoid arthritis agent in the U.S. as part of the merger agreement between the two firms

You may also be interested in...



Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005

The first supplemental BLA filing for Rituxan for the treatment of rheumatoid arthritis is slated for the fourth quarter of 2005, Roche Medical Science Department Head Guido Magni said

Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005

The first supplemental BLA filing for Rituxan for the treatment of rheumatoid arthritis is slated for the fourth quarter of 2005, Roche Medical Science Department Head Guido Magni said

Roche Pipeline Potency Validates No-Merger Stance, Company Says

Roche has the third largest pipeline of new molecular entities in development in the drug industry, the company maintained during an R&D day in New York City May 6

Related Content

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel